Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study
Abstract Introduction Anxiety and depression are frequently associated with migraine, and antidepressant use can complicate treatment. These analyses assessed the safety and tolerability of rimegepant in participants with migraine and anxiety and/or depression, or using selective serotonin reuptake...
Saved in:
Main Authors: | David Kudrow, Susan Hutchinson, Glenn C. Pixton, Terence Fullerton |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2024-11-01
|
Series: | Pain and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40122-024-00675-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
by: Hans-Christoph Diener, et al.
Published: (2025-02-01) -
The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: Monika Remenčiūtė, et al.
Published: (2024-05-01) -
Clinical Pharmacokinetics of Atogepant in Healthy Japanese and White Adults
by: Ramesh R. Boinpally, et al.
Published: (2025-01-01) -
Rimegepant for the treatment of migraine
by: Amnon A. Berger, et al.
Published: (2022-10-01) -
Epidemiology of clinically significant migraine in Israel: a retrospective database study
by: A. Shifrin, et al.
Published: (2025-02-01)